The myth of measurable disease in ovarian cancer

Journal of Clinical Oncology

Volumn 21, Issue 16, 2003, Pages 3013-3015

  Markman, Maurie ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; DOCETAXEL; PACLITAXEL; TOPOTECAN;

CANCER RESEARCH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG DOSE REGIMEN; EDITORIAL; HUMAN; LABORATORY TEST; OBSERVER VARIATION; OVARY CANCER; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SOLID TUMOR; FEMALE; OVARY TUMOR; PATHOLOGY; TREATMENT OUTCOME;

CA-125 ANTIGEN; FEMALE; HUMANS; OBSERVER VARIATION; OVARIAN NEOPLASMS; TREATMENT OUTCOME;

EID: 0042914728     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.08.148     Document Type: Editorial

References (15)

1. Miller AB, Hoogstraten B, Staquet M, et al: Reporting results of cancer treatment. Cancer 47:207-214, 1981
2. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205-216, 2000
3. Moertel CG, Hanley JA: The effect of measuring error on the results of therapeutic trials in advanced cancer. Cancer 38:388-394, 1976
4. Warr D, McKinney S, Tannock I: Influence of measurement error on assessment of response to anticancer chemotherapy: Proposal for new criteria of tumor response. J Clin Oncol 2:1040-1046, 1984
5. Prefontaine M, Gelfand AT, Donovan JT, et al: Reproducibility of tumor measurement in ovarian cancer: A study of interobserver variability. Gynecol Oncol 55:87-90, 1994
6. Gwyther S, Bolis G, Gore M, et al: Experience with independent radiological review during a topotecan trial in ovarian cancer. Ann Oncol 8:463-468, 1997
7. Kaye SB, Piccart M, Aapro M, et al: Docetaxel in advanced ovarian cancer: Preliminary results from three phase II trials. Eur J Cancer 31A:S14-S17, 1995
8. Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD, et al: European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: High-dose versus low-dose and long versus short infusion. J Clin Oncol 12:2654-2666, 1994
9. Hopper KD, Kasales C, Van Slyke MA, et al: Analysis of interobserver and intraobserver variability in CT tumor measurements. AJR Am J Roentgenol 167:851-854, 1996
10. Rustin GJS, Nelstrop AE, McClean P, et al: Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125. J Clin Oncol 14:1545-1551, 1996
11. Bridgewater JA, Nelstrop AE, Rustin GJS, et al: Comparison of standard and CA-125 response criteria in patients with epithelial ovarian cancer treated with platinum or paclitaxel. J Clin Oncol 17:501-508, 1999
12. Rustin GJS, Nelstrop AE, Bentzen SM: Selection of active drugs for ovarian cancer based on CA-125 and standard response rates in phase II trials. J Clin Oncol 18:1733-1739, 2000
13. Davelaar EM, Bonfrer JMG, Verstraeten RA, et al: CA 125, a valid marker in ovarian carcinoma patients treated with paclitaxel? Cancer 78:118-127, 1996
14. Morgan RJ Jr, Speyer J, Doroshow JH, et al: Modulation of 5-fluorouracil with high-dose leucovorin calcium: Activity in ovarian cancer and correlation with CA-125 levels. Gynecol Oncol 58:79-85, 1995
15. Markman M, Kennedy A, Webster K, et al: Declining CA-125 in an ovarian cancer patient with progression of measurable disease: A rational hypothesis for discordant results. Gynecol Oncol 77:321-322, 2000